Cisplatin, Ifosfamide, Methotrexate and Vinblastine Combination Chemotherapy for Metastatic Urothelial Cancer

Abstract

The cisplatin, ifosfamide, methotrexate and vinblastine regimen appeared active in patients with metastatic urothelial carcinoma. This regimen was associated with significant but manageable hematological toxicity and the incidence of mucositis or renal impairment was low. Prospective randomized studies are needed to assess whether the addition of ifosfamide to other active agents will improve the survival of patients with this disease.